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Objective. To assess the effect of abatacept (CTLA4Ig), which limits T cell activation, on homeostasis of CD41 T cell subsets and T cell-dependent B cell hyperactivity in patients with primary Sj€ ogren's syndrome (SS).
Methods. Fifteen patients with primary SS treated with abatacept were included. Circulating CD41 T cell and B cell subsets were analyzed by flow cytometry at baseline, during the treatment course, and after treatment was completed. CD41 effector T cell subsets and Treg cells were identified based on expression of CD45RA, CXCR3, CCR6, CCR4, CXCR5, programmed death 1, inducible costimulator (ICOS), and FoxP3. Serum levels of anti-SSA/anti-SSB and several T cell-related cytokines were measured. Expression of ICOS and interleukin-21 (IL-21) protein was examined in parotid gland tissue at baseline and after treatment. Changes in laboratory parameters and associations with systemic disease activity (EULAR Sj€ ogren's Syndrome Disease Activity Index [ESSDAI] ) over time were analyzed using generalized estimating equations.
Results. Abatacept selectively reduced percentages and numbers of circulating follicular helper T (Tfh) cells and Treg cells. Other CD41 effector T cell subsets were unaffected. Furthermore, expression of the activation marker ICOS by circulating CD41 T cells and expression of ICOS protein in parotid gland tissue declined. Reduced ICOS expression on circulating Tfh cells correlated significantly with lower ESSDAI scores during treatment. Serum levels of IL-21, CXCL13, anti-SSA, and anti-SSB decreased. Among circulating B cells, plasmablasts were decreased by treatment. After cessation of treatment, all parameters gradually returned to baseline.
Conclusion. Abatacept treatment in patients with primary SS reduces circulating Tfh cell numbers and expression of the activation marker ICOS on T cells. Lower numbers of activated circulating Tfh cells contribute to attenuated Tfh cell-dependent B cell hyperactivity and may underlie the efficacy of abatacept.
Primary Sj€ ogren's syndrome (SS) is a systemic autoimmune disease characterized by dry eyes and mouth, associated with infiltration of lacrimal and salivary glands by T and B lymphocytes (1) . Patients with primary SS may also have a diversity of extraglandular manifestations, such as fatigue and musculoskeletal, lung, and skin involvement.
B cell hyperactivity is a prominent feature of primary SS, reflected by hypergammaglobulinemia and autoantibody production, among others (2) . Consistent with this notion, we showed that B cells from primary SS patients, including antigen-inexperienced naive B cells, express elevated levels of the B cell receptor signaling molecule Bruton's tyrosine kinase (BTK) (3) . Elevated BTK levels have been linked to T cell-mediated autoimmune pathology in both rheumatoid arthritis (RA) and primary SS, indicating that there is a proinflammatory feedback loop between B cells and CD41 T cells (3) . Although in principle, all CD41 effector T cell subsets can provide help to B cells, follicular helper T (Tfh) cells are considered to be the most effective cells involved in T celldependent activation of B cells, leading to humoral immune responses (4) . Tfh cells facilitate generation of autoantibodies and formation and maintenance of germinal centers (GCs) (5) . The majority of Tfh cells are located in secondary lymphoid organs, where they characteristically express CXCR5, programmed death 1 (PD-1), inducible costimulator (ICOS), and the transcription factor Bcl-6 (5). CD41 T cells with a similar phenotype, called circulating Tfh cells, have been found in peripheral blood (6) . The transcriptional profile of circulating Tfh cells resembles that of classic Tfh cells located in lymphoid organs, except that circulating Tfh cells do not express Bcl-6 (7). It remains to be elucidated whether circulating Tfh cells are precursor cells of classic Tfh cells, derive from these cells, or both (8) .
Recently, Rao et al (9) showed that another CD41 T cell subset, defined as CXCR5-PD-1 high and provisionally named peripheral helper T (Tph) cells, also promotes B cell responses and that this subset is pathologically expanded in RA patients. Like circulating Tfh cells, Tph cells may functionally resemble classic Tfh cells. Upon activation, Tfh, circulating Tfh, and Tph cells up-regulate costimulatory molecules essential for interaction with B cells, including PD-1 and ICOS (10, 11) . In addition, all 3 subsets can secrete interleukin-21 (IL-21), which is critical for the support of B cell proliferation and differentiation (12) .
Within the peripheral CD41 T cell compartment of patients with B cell-mediated autoimmune diseases, increased frequencies of circulating Tfh cells are commonly seen (5). In patients with primary SS, proportions of circulating Tfh cells and serum levels of their signature cytokine IL-21 are increased (6, (13) (14) (15) . Tfh cells may be present in the target tissue as well, since elevated protein levels of IL-21 have been found in minor salivary glands (13) . Although circulating Tfh cells are a major source of IL-21, we cannot exclude the possibility that other cell types that produce IL-21, such as Th17 cells, natural killer T cells, and Tph cells, are at least partly responsible for this increase in IL-21 levels (16). Lowering of IL-21-producing T cells may reduce T cell-dependent B cell hyperactivity in patients with primary SS and is therefore a feasible treatment option.
Abatacept is a fully human fusion molecule combining CTLA-4 with IgG Fc that binds to CD80/86 and consequently impairs CD28-mediated T cell costimulation (17) . As a result, T cell-dependent B cell activation may be reduced, both indirectly by inhibiting dendritic cell-mediated differentiation of naive T cells into CD41 effector T cells and directly by blocking T cell-B cell interaction (18, 19) . To date, 2 open-label studies have evaluated the efficacy of abatacept in primary SS (20, 21) . Adler et al (21) observed histologic, cellular, and serologic changes in response to treatment, including a decrease in local Treg cells and serum gamma globulins. They also observed a small, but significant, increase in salivary gland function after treatment. The study by Meiners et al (20) showed that abatacept improves systemic disease activity and patient-reported symptoms, as measured by the EULAR Sj€ ogren's Syndrome Disease Activity Index (ESSDAI) and Patient Reported Index (20) . That study further showed that salivary gland function remained stable during treatment (24 weeks) and during follow-up after cessation of treatment (24 weeks).
Although clinical effects seem promising, the effects of abatacept on human T cells in vivo and on T cell-dependent B cell hyperactivity in primary SS remain elusive. Therefore, the aim of this study was to assess the effect of abatacept on the phenotypic distribution of circulating CD41 T cell and B cell subsets as well as on T celldependent B cell hyperactivity. We show that the numbers of circulating Tfh cells were predominantly affected by abatacept treatment. Importantly, ICOS expression on CD41 T cells also declined, both in peripheral blood and parotid gland tissue. The decrease in ICOS expression on circulating Tfh cells correlated significantly with the reduction in systemic disease activity, as measured by ESSDAI, over time.
PATIENTS AND METHODS
Study population. This was a prospective, single-center, open-label study of patients with early and active primary SS (n 5 15) (20) . All patients fulfilled the American-European Consensus Group criteria for primary SS (22) . Patients had not previously received any biologic disease-modifying antirheumatic drug, and immunosuppressants, including hydroxychloroquine and oral prednisone, were discontinued before inclusion. Baseline characteristics of the patients are displayed in Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40165/abstract. In addition, 15 age-and sex-matched healthy individuals (mean 6 SD age 45 6 11 years; 12 women) were included as healthy controls. All patients and healthy controls provided written informed consent. The study was approved by the Medical Ethics Committee of the University Medical Center Groningen (METc2009.371).
Study procedures. Patients were treated with abatacept for 24 weeks (;10 mg/kg by intravenous infusion on days 1, 15, and 29 and every 4 weeks thereafter) (20) . Follow-up was conducted at weeks 4, 12, and 24 (while receiving treatment) and weeks 36 and 48 (after completing treatment). Serum and EDTA and lithium-heparinized blood samples were obtained at baseline and during follow-up. Peripheral blood mononuclear cells (PBMCs) were immediately isolated from lithium-heparinized blood as previously described (23) , cryopreserved using Nalgene Mr. Frosty boxes, and stored at 21968C. Parotid gland biopsy specimens were obtained at baseline and at week 24 of follow-up. Systemic disease activity was measured using ESSDAI and Clinical ESSDAI (ClinESSDAI) (ESSDAI without the biologic domain) (24, 25) .
Assessment of circulating CD41 T cell and B cell subsets. Absolute numbers of circulating CD41 T cells and B cells were measured in fresh EDTA blood samples using the Multitest Trucount method (Becton Dickinson). Fresh blood samples were stained with antibodies directed against human CD3, CD4, CCR7, and CD45RO (Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40165/abstract), lysed, washed, and analyzed by flow cytometry for the presence of naive (CCR71CD45RO-), central memory (CCR71CD45RO1), effector memory (CCR7-CD45RO1), and terminally differentiated (CCR7-CD45RO-) CD41 T cells (26) . In a separate experiment, cryopreserved PBMCs were thawed, 2 million cells were fluorescence labeled for effector memory CD41 T cell subset analysis, and 2 million cells were fluorescence labeled for B cell subset analysis (see Supplementary Table 2 for a list of the antibodies used). CD41 effector memory T cell subsets were identified by chemokine receptor patterns (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40165/abstract). One patient was excluded from CD41 effector memory T cell analysis because of consistently aberrant CD45RA expression, which precluded analysis of memory subsets. Flow cytometric measurements were performed on a FACS LSRII flow cytometer (Becton Dickinson), and data were analyzed using Kaluza (Beckman Coulter) and FlowJo (Tree Star) software.
Quantification of cytokines and anti-SSA/SSB IgG titers in serum. Serum CXCL13 levels were quantified as part of a custom-made ProcartaPlex Multiplex Immunoassay (eBioscience), which also included interferon-g (IFNg), IL-4, IL-17, IL-22, and IL-10. Serum IL-21 levels were measured by an inhouse enzyme-linked immunosorbent assay (ELISA) using purified anti-human IL-21 and biotin-conjugated anti-human IL-21 (eBioscience). Serum titers of anti-SSA and anti-SSB IgG were measured by an in-house ELISA using Ro 52, Ro 60, and La antigens (Euro-Diagnostica) and horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc (Bethyl Laboratories).
Immunohistochemistry. For immunohistochemical staining of ICOS expression in salivary glands, formalin-fixed, paraffin-embedded sections (3 mm) of parotid gland tissue were incubated for 1 hour at room temperature with primary antibodies to ICOS (clone SP98; Thermo Scientific). Prior to incubation, heat-induced epitope retrieval (HIER) was performed using EDTA buffer (pH 8). Anti-ICOS antibodies were visualized using an HRP-linked detection system with diaminobenzidine (Dako), and sections were analyzed for staining using the Positive Pixel Count algorithm (version 9.1) in Aperio ImageScope (Aperio Technologies). Only foci were depicted for analysis, and the relative area stained within these foci was calculated by dividing the positive pixel count by the total pixel count. HIER was performed on consecutive sections using citrate buffer (pH 6), and sections were incubated overnight at 48C with primary antibody to IL-21 (polyclonal; Novus Biologicals) and the next day for 1 hour at room temperature with anti-CD4 (clone 1F6; Abcam). Two-color immunofluorescence visualization of staining was performed using Alexa Fluor 488-conjugated anti-mouse IgG and Alexa Fluor 594-conjugated anti-rabbit IgG tyramide SuperBoost kits (Thermo Scientific) according to the manufacturer's protocol. Fluorescence images were acquired using a TissueFAX system, and data were analyzed using TissueQuest software (TissueGnostics).
Statistical analysis. All results are presented as the median (interquartile range [IQR] ). Mann-Whitney U tests were used to compare differences between patients and healthy controls. Generalized estimating equations (GEEs) with exchangeable correlation structure were used to analyze changes in laboratory parameters and associations with systemic disease activity over time within subjects (27) . Data from baseline up to week 24 were compared with baseline to assess changes while patients were receiving treatment. Data from week 24 to week 48 were compared with week 24 to assess changes when patients were no longer receiving treatment. Wilcoxon's matched pairs tests were used to compare histologic parameters at baseline and week 24 . P values less than 0.05 (2-tailed) were considered significant. Statistical analysis was performed using SPSS Statistics version 23 (IBM).
RESULTS
Abatacept affects the distribution of CD41 T cell subsets. In patients with primary SS, total numbers of circulating CD41 T cells at baseline were ;35% lower than in healthy controls (median 0.59 3 10 /liter [IQR 0.82-0.96] in healthy controls; P 5 0.022). Systemic disease activity was relatively high in our study population, and it has previously been shown that CD41 T cell numbers are most strongly decreased in primary SS patients with high ESSDAI scores (28) . Within the CD41 T cell fraction, proportions of naive and terminally differentiated CD41 T cells were not significantly altered in primary SS patients at baseline compared with healthy controls (Figures 1A and C) . Proportions of central memory CD41 T cells were significantly decreased ( Figure 1B ), whereas proportions of effector memory cells were significantly increased ( Figure 1D ), in primary SS patients compared with healthy controls. These results indicate that the primary SS patients studied had a relatively expanded effector memory CD41 T cell compartment, at the expense of central memory CD41 T cells. Consistent with this finding, it has been shown that primary SS patients have a higher proportion of HLA-DR1CD41 T cells, indicating recent activation of T cells (28) .
Abatacept treatment resulted in a slight increase in total numbers of CD41 T cells (;5%) at week 4 only (data not shown). Proportions of effector memory CD41 T cells, and to a lesser extent central memory CD41 T cells, were significantly decreased in patients treated with abatacept ( Figures 1B and D) , while proportions of naive and terminally differentiated CD41 T cells were significantly increased ( Figures 1A and C) . The distribution of these 4 differentiation subsets was, however, not entirely 1852 VERSTAPPEN ET AL normalized to the distribution seen in healthy controls ( Figure 1 ). Also, absolute numbers of effector and central memory CD41 T cells were significantly reduced by abatacept (P 5 0.009 and P , 0.001, respectively) (data not shown). These findings indicate that the two memory CD41 T cell subsets in particular are affected by abatacept, illustrating the dependency of memory T cell formation or maintenance on CD28-mediated costimulation (29) . Abatacept specifically reduces circulating Tfh and Treg cell numbers in peripheral blood. Next, the various effector subsets and peripheral Treg cells that are comprised within the peripheral CD41 T cell fraction were studied in more detail. Baseline proportions of circulating Tfh cells (CD45RA-CXCR51PD-11), Th17 cells (CD45RA-CXCR5-CXCR3-CCR41CCR61), and peripheral Treg cells (CD45RA-FoxP31) were all significantly increased in primary SS patients compared with healthy controls (Figure 2A ). These results are consistent with our previous findings in a different study population (30) . The recently described Tph cells (CXCR5-PD-1 high ), which functionally resemble Tfh cells and provide B cell help (9), were also significantly increased in the peripheral blood of primary SS patients compared with healthy controls (Figure 2A ). Their overall frequencies and numbers, however, remained much lower than circulating Tfh cells. To explore the activation state of effector T cell subsets, we also analyzed the expression levels of ICOS on these cells. All effector subsets from primary SS patients expressed significantly higher levels of ICOS than did healthy controls (data not shown), with the highest relative increase in expression seen on circulating Tfh cells ( Figure  2B ). Apparently, effector CD41 T cells from primary SS patients are in a hyperactive state, which enhances their capacity to interact with antigen-presenting cells. ICOS expression was also present on peripheral Treg cells, but no significant difference in expression level between primary SS patients and healthy controls was observed.
To assess the extent to which abatacept modulates T cell activation in primary SS, we examined different CD41 effector memory subsets at various time points while patients were receiving treatment and after they had stopped treatment. The most pronounced effects of abatacept were seen on circulating Tfh cells. Treatment resulted in a significant decrease in absolute numbers and proportions of this subset over time ( Figures 2D and E) . Absolute Figure 1) . The decrease in circulating Tfh cells during treatment was accompanied by normalization of ICOS expression levels on these cells to levels seen in healthy controls ( Figures 2F and G) . The decrease in ICOS levels was further reflected by a decrease in the proportion of CXCR51PD-11ICOS1CD41 cells ( Figure 2H ). ICOS expression on other effector subsets and on peripheral Treg cells was also reduced (data not shown). Although the proportions of Tph cells were also decreased in patients treated with abatacept (P 5 0.003 for week 0-24, by GEE), their absolute numbers only tended to decrease (P 5 0.074) ( Figure 3B ). Thus, Tph cells were less affected by abatacept than (PD-1 high ) circulating Tfh cells ( Figure 3C ). This selective decrease in circulating Tfh cells was reflected by an increased ratio of CXCR5-PD-1 high Tph cells to CXCR51PD-1 high Tfh cells during treatment ( Figure 3D ). After patients stopped treatment, the numbers and proportions of circulating Tfh cells, peripheral Treg cells, and Tph cells, as well as ICOS expression levels on all subsets, reverted to baseline levels, underlining their (partial) dependency on CD28 signaling.
Reduced numbers of circulating plasmablasts in primary SS patients treated with abatacept. Since circulating Tfh cells were reduced by abatacept, and given the notion that Tfh cells support the formation of plasmablasts, this B cell subset might also be affected by Reduced serum IL-21 and CXCL13 levels in primary SS patients treated with abatacept. We subsequently analyzed serum levels of signature cytokines of the various effector CD41 T cell subsets. IL-21, the signature cytokine of Tfh cells, was detectable in 12 patients at baseline (80%). In these patients, abatacept treatment significantly decreased IL-21 levels ( Figure 4A ). In addition to IL-21, Tfh cells can produce the homeostatic chemokine CXCL13. Serum levels of this chemokine were also significantly reduced by abatacept treatment ( Figure 4B ). After patients stopped treatment, serum levels of both IL-21 and CXCL13 returned to baseline values ( Figures 4A and B) . Signature cytokines of other CD41 effector subsets were not significantly altered by treatment (IL-17 and IL-22) or remained undetectable in serum at all time points (IFNg, IL-4, and IL-10), which may be a consequence of the sensitivity of the assay.
Abatacept affects SSA and SSB antibody titers. Since serum IL-21 levels, numbers of circulating Tfh cells, and plasmablasts were all reduced by treatment, we next investigated whether concentrations of autoantibodies in serum were also affected by abatacept. Consistent with the observed decrease of ;20% in total IgG (20) , levels of IgG antibodies to both isoforms of SSA (Ro 52 and Ro 60), and to SSB (La) were decreased to a similar extent during treatment (Figures 4C-E) . Anti-Ro 52 and anti-Ro 60 ABATACEPT IN PRIMARY SJ € OGREN'S SYNDROMElevels, but not anti-La levels, increased significantly after cessation of treatment. Thus, abatacept limits maintenance of IgG production, including autoantibodies, which is likely a result of reduced Tfh cell-mediated activation of B cells. Decreased ICOS expression in the parotid glands of patients treated with abatacept. To explore whether the effects on circulating Tfh cells were also reflected in the inflamed glandular tissue, we analyzed expression of ICOS and IL-21 protein in the parotid gland tissue of patients with primary SS before and after treatment. We recently showed that the focus score and absolute numbers of CD31 T cells/mm 2 parenchyma were not altered by treatment (31) . In the present study, immunohistochemical staining revealed that ICOS expression within foci was significantly decreased by treatment (Figure 5) . Different levels of staining (weak, medium, and strong) could be distinguished at baseline; after treatment, strong staining was nearly absent ( Figure 5B ). In contrast to ICOS expression, numbers of CD41IL-211 cells in parotid glands were not significantly affected by treatment (data not shown).
Correlation of changes in laboratory parameters with systemic disease activity. ESSDAI and Clin-ESSDAI were used to assess the clinical relevance of the Tfh cell-related changes observed during abatacept treatment. The decline in ICOS expression levels on circulating Tfh cells, but not numbers of circulating Tfh cells, was significantly associated with the decrease in ESSDAI and ClinESSDAI scores (Figure 6 ). Changes in serum levels of CXCL13, anti-Ro 60, and rheumatoid factor (RF) induced by abatacept over time were also significantly associated with a decrease in ESSDAI and ClinESSDAI, whereas changes in the number of peripheral Treg cells and levels of total IgG, IL-21, anti-Ro 52, and anti-La were not ( Figure 6 ).
DISCUSSION
Previously, we showed in an open-label study that abatacept is effective for the treatment of primary SS (20) .
In the present study, we demonstrated that abatacept predominantly targets circulating Tfh cells, which may help to explain the underlying mechanism of clinical efficacy. Abatacept resulted not only in a decrease in the numbers and activation state of circulating Tfh cells, but also in reduced serum levels of Tfh cell-related cytokines (i.e., IL-21 and CXCL13). A decrease in circulating Tfh cells likely contributed to the observed decrease in circulating plasmablasts and anti-SSA/SSB titers. Furthermore, abatacept reduced the numbers of peripheral Treg cells and tended to reduce the numbers of the novel Tph cell subset, defined as CXCR5-PD-1 high , but did not affect Th1, Th2, or Th17 cells. Taken together, these findings indicate that the effects of abatacept are selective and reduce Tfh cell activity, thereby attenuating Tfh cell-dependent B cell hyperactivity in primary SS patients.
Although the number of patients studied was small (n 5 15), baseline proportions of circulating Tfh cells were significantly elevated in the patients compared with healthy controls. These results are consistent with previous findings in primary SS (6, 14, 32) . A new observation is that circulating Tfh cells from primary SS patients have a 3-fold higher expression level of ICOS compared to healthy controls. Since ICOS is highly up-regulated upon activation (11, 33) , together with CXCR5 and PD-1, Tfh cells in patients with primary SS are likely in a hyperactive state. Increased ICOS expression by CXCR51CD41 T cells provides a stronger costimulatory signal to the B cell via ligation of ICOSL (34, 35) . In turn, this interaction promotes expression of IL-21 by Tfh cells (36) . It is plausible that ICOS/ ICOSL-mediated cross-talk between Tfh cells and B cells is a critical step in primary SS-associated B cell hyperactivity. The importance of a positive feedback loop between B cells and T cells in autoimmune pathology is illustrated by findings that BTK overexpression in B cells leads to systemic autoimmunity in mice, together with higher numbers of splenic Tfh cells and higher expression levels of ICOS on T cells, compared with wild-type mice (37) .
Importantly, we demonstrated a selective decrease in the numbers and proportions of circulating Tfh cells in primary SS patients treated with abatacept, to levels normally seen in healthy controls. Furthermore, we showed that activation of circulating Tfh cells, as revealed by ICOS expression, was strongly diminished by this treatment. In addition to its direct role in B cell activation, ICOS expression is essential for the maintenance and accumulation of Tfh cells (38, 39) . Normalization of ICOS levels in primary SS patients by abatacept, as a result of less CD28-mediated activation, may therefore be the key event leading to fewer Tfh cells. In RA patients, a decrease in circulating Tfh cells has also been observed after abatacept treatment (40) . In the latter study, only one time point after treatment was evaluated, and expression of ICOS and other possible activation markers were not measured.
From animal studies it has become clear that abatacept limits activation of CD41 T cells after antigen exposure (19, 41) . More specifically, it also prevents antigeninduced expression of ICOS and PD-1 on CD41 T cells, and autoantibody formation in mice (41) . The latter observations are consistent with the decrease in total IgG and RF observed in our cohort of abatacept-treated primary SS patients (20) as well as with the decline in ICOS expression on CD41 T cells, plasmablasts, and anti-SSA and anti-SSB titers observed in the present study. Abatacepttreated patients with RA in remission also have reduced serum titers of autoantibodies (42) . It has been proposed that abatacept blocks survival signals to CD28-expressing autoreactive plasma cells, leading to apoptosis and consequently also to a decline in autoantibody titers (43, 44) . However, we were unable to detect CD281 plasma cells in parotid gland tissue from primary SS patients (Kroese FGM: unpublished observations). The other explanation is that at least some of the autoantibody-producing plasma cells are relatively short-lived cells, which are not replaced by newly generated plasma cells in the absence of T cell help. In support of this notion, anti-Ro 60 clonotypes in the serum of primary SS patients are continuously replaced, which suggests that at least part of these IgG autoantibodies are derived from short-lived plasma cells (45) .
In addition to the effects on circulating Tfh cells, abatacept reduces numbers and proportions of peripheral Treg cells. This can be explained by the requirement of CD28 signaling for peripheral Treg survival and proliferation (46) . Consistent with our findings, Adler et al (21) observed a decrease in CD31FoxP31 cell numbers in labial salivary gland sections from primary SS patients after abatacept treatment. It is likely that the peripheral and local decrease in peripheral Treg cells is an effect of less CD41 T cell activation. Since the suppressive capacity of the remaining Treg cells is not known, the functional implication of this effect is not clear.
Low numbers of Tfh cells (CD31Bcl61) have also been detected in minor salivary glands of primary SS patients (47) . Here they occur in close association with Bcl61 GC B cells. In our study population, Bcl61 cells were rarely detected in parotid gland tissue sections in the absence of GCs (data not shown). Since ICOS is highly expressed on Tfh cells and IL-21 is the signature cytokine of Tfh cells, we alternatively analyzed the presence of ICOS1 cells and CD41IL-211 cells by immunohistochemistry/immunofluorescence in parotid gland tissue before and after treatment with abatacept. ICOS staining was significantly lowered by treatment, and strongly ICOSpositive cells, which may represent Tfh cells, were nearly absent after treatment. As mentioned above, these reduced levels may result in less efficient costimulation of antigen-presenting cells in salivary gland tissue. Tfh cells in follicles require continuous signals from B cells via ICOS/ ICOSL ligation. When ICOSL is blocked, Tfh cells lose CXCR5 expression and migrate back to the T cell zone, which results in a collapse of GCs (38) . Interestingly, in our study population a decrease in GCs in parotid gland tissue was seen after abatacept treatment (31) .
Although ICOS expression in parotid gland tissue is reduced by treatment, the number of CD41IL-211 cells does not change significantly. Apparently, CD41 T cells that reside in the gland are still activated by antigenpresenting cells and stimulated to produce cytokines via costimulatory pathways other than CD28-CD80/86 and ICOS/ICOSL, or IL-21 production is maintained by autocrine regulation and/or continuous presence of IL-6. Possibly, IL-21 is still produced after abatacept treatment by cells other than classic ICOS high Tfh cells, since IL-21 production is not restricted to Tfh cells (16) . For example, IL-21-producing CXCR5-PD-1 high CD41 T cells were abundant in the joint tissue of RA patients, and their frequency was higher than CXCR51PD-1 high CD41 Tfh cells (9) . In addition, a novel population of IL-211 Th1 cells was recently identified in salivary gland tissue from NOD mice (48), a murine model of SS, and this population may also be responsible for glandular IL-21 production in primary SS patients.
In the present study, we showed that the decline in ICOS expression levels on circulating Tfh cells was significantly associated with the decrease in systemic disease activity. Changes in the levels of CXCL13 and autoantibodies (RF and anti-Ro 60) were also associated with a decrease in systemic disease activity. It is known that positivity for RF and anti-SSA, of which anti-Ro 60 usually makes up the largest part, are both associated with the presence of extraglandular symptoms (49) . Also, serum levels of CXCL13 have been associated with systemic disease activity in primary SS (50) . Attenuation of the ABATACEPT IN PRIMARY SJ € OGREN'S SYNDROMEhyperactivated state of Tfh cells by abatacept, with a concomitant decrease in serum RF, anti-SSA, and CXCL13 levels, probably underlies the amelioration of systemic disease activity. How these factors influence systemic disease activity is not yet understood and remains to be elucidated. In contrast, the presence of glandular IL-21-producing CD41 T cells was not affected by treatment in this study. Perhaps patients should be treated for a longer period of time to significantly reduce the influx of newly formed effector T cells into the glands. Alternatively, simultaneous blockade of other costimulatory pathways or direct targeting of IL-6 or IL-21 could be of additional value to target Tfh cell activity in the glands. In conclusion, abatacept affects circulating Tfh cell activation and ICOS expression and concomitantly results in amelioration of systemic disease activity. Our findings support the notion that Tfh cell-dependent B cell hyperactivity plays a central role in primary SS pathogenesis. We postulate that the cross-talk between Tfh and B cells is a key target for successful therapeutic interventions in primary SS.
